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ScienceDirectThe specificity of RNA-guided nucleases has gathered
considerable interest as they become broadly applied to basic
research and therapeutic development. Reports of the simple
generation of animal models and genome engineering of cells
raised questions about targeting precision. Conflicting early
reports led the field to believe that CRISPR/Cas9 system was
promiscuous, leading to a variety of strategies for improving
specificity and increasingly sensitive methods to detect off-
target events. However, other studies have suggested that
CRISPR/Cas9 is a highly specific genome-editing tool. This
review will focus on deciphering and interpreting these
seemingly opposing claims.
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First generation methods to detect potential
off-target sites: computational prediction and
in vitro screens
The RNA-guided clustered, regularly interspaced, short
palindromic repeat (CRISPR)/CRISPR-associated pro-
tein 9 (Cas9) endonuclease system has taken the genome
editing field by storm. The complex consists of the Cas9
nuclease protein and a single guide RNA (sgRNA) that
targets a specific DNA sequence through RNA-DNA
base pairing (Figure 1) [1]. The most widely used
Cas9, derived from Streptococcus pyogenes, targets a 20 nu-
cleotide DNA sequence immediately followed by a 50-
NGG-30 protospacer-adjacent motif (PAM) [1]. The first
studies of Cas9 specificity focused on off-target cleavage
activity at genomic regions that were identified by
computational prediction based on similarity to the target
sequence [2,3,4,5], in vitro cleavage assays [6], or high-
throughput reporter screens [7] (Figure 2, top). Predicted
sites were analyzed for cleavage using a PCR-based
assay. Some studies suggested high frequency of
CRISPR/Cas9 activity [2,5], which alarmed the entireCurrent Opinion in Chemical Biology 2015, 29:72–78 field and established expectations for follow-up studies to
identify high off-target activity. However, other studies
found modest or low off-target activity at predicted
genomic sites [3,6] (Table 1). Results varied widely,
even within a single research study. For example, among
the six target sites tested by Fu and colleagues [2], no
off-target sites were identified for two targets (RNF2
and FANCF), only one off-target site was detected for
EMX1, while 4, 12 and 7 off-target sites were observed
for VEGFA sites 1, 2 and 3, respectively. Thus, there
was a clear distinction between very high target speci-
ficity of some sgRNAs (RNF2, FANCF), while others
were very promiscuous (VEGFA sites 2 and 3) (Table 1).
Despite this variance, the promiscuous VEGFA sgRNAs
became the archetypal poster child for off-target activity
and would be used in many subsequent studies. Al-
though it certainly makes sense to use promiscuous
sgRNAs to test new methods for off-target site detec-
tion and avoidance, one should not assume that
CRISPR/Cas9 per se has high off-target activity. Perhaps
the most accurate conclusion from these early studies
would be that CRISPR/Cas9 has the potential to be
highly specific or lead to high-frequency off-target ac-
tivity depending on the choice of sgRNA.
This conclusion notwithstanding, concerns about spec-
ificity led to several strategies to reduce off-target
effects while retaining efficient on-target cleavage
(reviewed in [8]). Heterodimeric Cas9 variants, such
as paired Cas9 nickases and dimeric Cas9-FokI
nucleases rely on targeting via two sgRNAs significantly
enhanced specificity [9,10]. Modified sgRNAs can ef-
fectively reduce off-target activity by, paradoxically, the
addition of two extra guanine nucleotides to the 50
end (GGN20-NGG) of the traditional sgRNA design
(GN19-NGG) [4], or the use of truncated sgRNAs
(GN17-NGGor GN18-NGG) [11,12]. In addition to mis-
matches, some sgRNAs can also tolerate DNA sequences
with an extra base (DNA bulge) or a missing base (sgRNA
bulge) [13] (Figure 3).
There is an expanding list of algorithms available that
search the genome for similar sites adjacent to the
Cas9 PAM, allowing a certain number of mismatches
to the target site [3,14,15–17]. However, since pre-
dictive first generation methods could only survey a
subset of potential off-target sites, a much larger num-
ber of off-target sites in the entire genome was
expected. This assumption highlighted the need for
unbiased and genome-wide detection of Cas9 off-target
activity.www.sciencedirect.com
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CRISPR/Cas9 specificity is dependent on its sgRNA. The Cas9 protein
(pink) complexes with a single guide RNA (sgRNA, red) at a DNA
target site that contains a protospacer adjacent motif (PAM, blue box).
The 50 end of the sgRNA forms a 20-bp heteroduplex with one strand
of the DNA. The binding or cleavage events facilitated by the Cas9/
sgRNA complex can be categorized as highly specific (no off-targets),
intermediate (1 to 5 off-targets) and promiscuous (6 or more off-
targets).Second generation methods: genome-wide
binding specificity of nuclease-inactive dCas9
The catalytically inactive dCas9 has been used as a
simple programmable DNA-binding platform for many
applications including transcriptional activation and re-
pression (CRISPRa and CRISPRi, respectively) [18–23].
Since dCas9 regulators do not possess nuclease activity,
several groups performed ChIP-seq (Chromatin Immu-
noprecipitation followed by high throughput sequencing)
to determine CRISPR/dCas9 binding specificity on a
genome-wide scale [24–27] (Figure 2, middle). Virtually
all studies observed the highest intensity binding at the
target site, suggesting a strong binding preference for
the target. However, less-intense off-target sites were
detected varying from a few to hundreds or thousands
of binding sites. The wide variation in off-target sites
observed between different groups was likely due to
differences in their experimental and analytical methods,
in addition to any differences between individual
sgRNAs. Off-target sites often contained motifs that were
identical to the PAM proximal target sequence. Overall,
these studies suggested that ChIP-seq identifies stable
dCas9 binding to genomic target sites as well as transient
binding of dCas9 to regions with partial complementarity
as it scans the genome. Transient binding of Cas9 and
dCas9 had been demonstrated in vitro and, interestingly,
DNA cleavage only occurred at target sites and not at sites
of transient interaction [28]. The lack of cleavage at
transient sites in vitro was borne out in vivo. In fact, somewww.sciencedirect.com studies were only able to observe cleavage at none or one
off-target site [24,25,27] (Table 1).
However, subsequent third-generation methods would
show that the near-perfect specificity of dCas9 in ChIP-
seq assays might be an underestimation of the true off-
target behavior of catalytically active Cas9. This discrep-
ancy might be attributed to different determinants for
Cas9 binding and nuclease activity, or structural differ-
ences between Cas9 and dCas9. Indeed a structure of
dCas9 bound to DNA showed the HNH endonuclease
domain located away from the scissile phosphate group of
the target DNA strand, suggesting activity-dependent
conformational rearrangements [29]. However, the results
of these studies are still valid for all dCas9 applications,
and generally showed that binding of dCas9 was very
highly specific.
Third generation methods: genome-wide
detection of Cas9-induced double strand
breaks
Double strand breaks (DSB) in the DNA of most species
can be repaired by a highly efficient but error-prone
nonhomologous end-joining pathway, leading to the ac-
cumulation of mutations at the breakpoint. Therefore,
the most intuitive and comprehensive approach to iden-
tify DSB induced by catalytically active Cas9 across the
whole genome is to search for mutations using whole
genome sequencing (WGS, Figure 2, bottom). WGS of
induced pluripotent stem cell (iPSC) clones generated by
CRISPR/Cas9 treatment suggested high specificity of
CRISPR/Cas9 [30,31]. In addition to the on-target site,
one WGS study identified one high-frequency off-target
that was not present in the reference genome, but rather
created by a single nucleotide variation in that particular
iPSC line [32]. This brings up the issue of sequence
variation between individual genomes that will need to
be addressed moving forward. Each genome is unique,
possibly leading to off-targets that are not present in one
individual but may be present in another. However, while
WGS can readily detect high-frequency events, it is
limited by the need of extensive sequencing depth.
The typical 30x-60x coverage of the genome is not suffi-
cient to identify low-level mutations. Digenome-seq also
relies on WGS sequencing of nuclease digested genomic
DNA, but Cas9-induced insertion and deletions are iden-
tified by their sequence signature rather by divergence
from the reference genome [33]. However, sequencing
depth and cost remains a limiting factor, especially when
using non-human cells.
The need for accurate and unbiased detection of Cas9-
induced off-targets on a genome wide scale has led
researchers to adopt and develop new methods (reviewed
in [8,34]). Integrase-deficient lentivirus vectors (IDLV)
were able to identify off-target sites by integrating
a marker gene at Cas9-induced DSBs [35], based onCurrent Opinion in Chemical Biology 2015, 29:72–78
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A diversity of methods has been used to predict or detect off-target sites. Each successive methodology attempted to be less biased and
interrogate more of the genome than the previous generation.methods developed earlier for zinc finger nucleases [36].
Depending on sgRNA used, detected off-targets varied
from zero to seven (Table 1), but no off-target sites were
observed with paired Cas9 nickases. A similar approach,
genome-wide unbiased identification of DSBs enabled
by sequencing (GUIDE-seq), identifies DSB by inserting
small barcoded pieces of DNA followed by high through-
put sequencing [37]. Among seven sgRNAs, off-target
activity varied widely from zero (RNF2) to as many as
151 off-targets (VEGFA site 2) (Table 1). Thus, these
studies recapitulated the same basic message that we
learned from the first generation methods, that
CRISPR/Cas9 cleavage has the potential for high or
low specificity depending on the sgRNA.
In addition to insertion and deletion mutations, Cas9 also
induces chromosomal translocations between breakpointsCurrent Opinion in Chemical Biology 2015, 29:72–78 at on-target and off-target sites and double strand break
hotspots that are independent of Cas9. Translocation
events can be determined by several methods, such as
GUIDE-seq [37] and high-throughput, genome-wide,
translocation sequencing (HTGTS) [38]. No transloca-
tion events were detected by HTGTS for two of the four
sgRNAs targeting the RAG1 locus. By contrast, a large
number of translocations was observed with the promiscu-
ous sgRNA (VEGFA site 2), whose high off target activity
has previously been reported [2,33,37] (Table 1). DSB
hot spots can vary between cell types, which may contrib-
ute to cell-type specific off-target effects. Recently, DSB
hotspots of individual genomes have been mapped reveal-
ing common and unique hotspots [39]. It will be interesting
to define determinants of DSB hotspots to reduce the
risk of deleterious consequences by irreversible changes
to the genetic information.www.sciencedirect.com
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Table 1
Categorized sgRNA specificity
Study Off-target
prediction/detection
method
Validation
ratea
sgRNA specificity based on validated off-target activity
Highly specific
(0 off-targets)
Intermediate
(1–5
off-targets)
Promiscuous
(>5 off-targets)
Computational
prediction &
in vitro screen
Mali et al. 2013 Reporter gene
screen
<1% n.d.b (artificial
target sites)
Cho et al. 2013 Computational &
exome capture
<1% C4BPB
CCR5
Fu et al. 2013 Computational <1% RNF2
FANCF
EMX1
VEGFA site 1
VEGFA site
2 (12)
VEGFA site
3 (7)
Hsu et al. 2013 Computational <1% EMX site 1
EMX site 3
Pattanayak
et al. 2013
Computational &
in vitro screen
<1% CLTA4 (3)
Cradick et al.
2013
Computational <1% 9 sgRNAsc 10 sgRNAsc
Lin et al. 2014 Computational
(gRNA and DNA
bulges)
<1% n.d.b (focus
on
DNA/RNA
bulges, not
mismatches)
Genome-wide
detection of
dCas9 binding
Wu et al. 2014 ChIP-seq <1%d Nonog-sg3
Phc1-sg1
Phc1-sg2
Nanog-sg2
Cecnic et al.
2014
ChIP-seq <1%d sgp53-3 sgp53-1
Kuscu et al.
2014
ChIP-seq <1%d
O’Geen et al.
2015
ChIP-seq &
sequence
capture
<1%d S1 S2
Gersbach
et al. 2015
ChIP-seq &
RNA-seq
3–17% IL1RN
HBG1/2
Genome-wide
detection of
DSBs and
NHEJ
Tsai et al. 2015 GUIDE-seq 80% RNF2 HEK
293 site 2
HEK
293 site 3
VEGFA site
1 (21)
VEGFA site
2 (151)
VEGFA site
3 (59)
EMX1 (15)
FANCF (8)
HEK293
site 1 (9)
HEK 293
site 4 (133)
Kim et al. 2015 Digenome-seq 7–10% HBB VEGFA (81)
Ran et al. 2015 BLESS 14–41% Pcsk9 EMX1-sg1 EMX-sg2 (12)
Frock et al. 2015 HTGTS (focus
on translocation)
n.d.b RAG1B RAG1A
Wang et al. 2015 IDLV 100%e WAS CR-3
TAT CR-4
TAT CR-6
WAS CR-5
TAT CR-1
WAS CR-4
(12)
a Validation rate serves only as a reference and is highly dependent on the sensitivity of the method, the number of sgRNAs tested, and the number of
potential off-target sites used for validation.
b n.d., not determined.
c Only one potential off-target site was examined.
d ChIP-seq detection is based on DNA binding while validation is based on DNA cleavage activity. Both methods have different specificity
determinants and cannot be directly compared.
e Additional sites that were not identified by IDLV were validated after computational prediction.
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Some sgRNAs allow binding or cleavage at variants of the target site.
In addition to single-base mismatches (a), some sgRNAs can tolerate
DNA sequences with an extra base ((b), DNA bulge) or a missing base
((c), sgRNA bulge).Conclusions and prospectus
It is evident that major differences in CRISPR/Cas9
specificity arise from sgRNAs themselves. Although some
sgRNAs have the potential to be highly specific, others
are promiscuous leading to hundreds of off-targets
(Table 1). Therefore, it would seem inappropriate to
suggest that the CRISPR/Cas9 platform per se is specific
or non-specific. The current challenge is to anticipate
which sgRNA will provide high on-target activity while
having minimal off-target effects. In this regard, CRISPR/
Cas9 maintains a technological advantage over zinc finger
and transcription activator-like effector (TALE) proteins,
which can also be highly specific but require more effort
to assembly each new protein to test.
A deeper analysis of Cas9 orthologs from other species
may reveal greater or less specificity for a given target site.
Cas9 orthologs often vary in target site and PAM require-
ments [22,40,41]. The genome-wide nuclease activity of
the S. aureus Cas9 was assessed using BLESS (direct in
situ breaks labeling, enrichment on streptavidin and next-
generation sequencing) [41]. Interestingly, SaCas9 dis-
played higher specificity than SpCas9. Furthermore, no
off-target activity was observed in the mouse neuroblas-
toma cell line or mouse liver after AAV delivery of SaCas9
and Pcsk9 sgRNAs [41]. Further analysis is also required
to understand how chromatin structure and sequence
context contribute to target site accessibility, as well
as on-target and off-target site recognition. Off-target
binding correlated with DNase I hypersensitive sites
(DHS) characteristic for accessible chromatin regions,Current Opinion in Chemical Biology 2015, 29:72–78 and preferentially localized to regions void of DNA
methylation [24–26]. Sequence features that contribute
to sgRNA efficiencies have been systematically assessed
in order to construct a predictive sequence model for the
design of CRISPR/Cas9 knockout experiments [14,42].
There was a distinct preference for a guanine nucleotide
immediately preceding the PAM site and nucleotide
composition downstream of the PAM site also contribut-
ed to sgRNA efficiency. More recently, sequence context
on sgRNA efficiency was also assessed for CRISPRi/
CRISPRa [14]. These studies again found the sequence
preference of CRISPRi/CRISPRa to be distinctly differ-
ent from CRISPR knockout experiments. Although these
models are not perfect, they are a step towards improve-
ment of sgRNA design for gene editing and regulation.
Solving the challenge of optimal sgRNA selection will
likely require large data sets of many sgRNAs in different
cell types. Cell types for which large amounts of genomic
data are already available, such as the ENCODE Tier
1 cell lines [43], would be more informative than the
HEK293 and U2OS cells used frequently in the past.
The number of off-target events that could be tolerated
by any sgRNA may also depend on the application.
Changes to the genome by a Cas9 endonuclease are
irreversible at off-target sites, which could lead to dele-
terious effects. One could argue that a single off-target
site is too much when genomic DNA is permanently
altered. Introducing CRISPR/Cas9 into a patient for gene
therapy, with the potential to modify millions of cells and
cell descendants, would require the highest specificity.
However, there may be few off-target events in any single
Cas9-treated iPSC, which could be clonally expanded and
off-target events verified by WGS of that one genome. A
modest number of off-target bindings might also be
acceptable when using dCas9 to regulate transcription
without altering the genetic content [18–20,23], even in
clinical applications.
In conclusion, the current data suggest that careful selec-
tion of the sgRNA used with SpCas9 can produce a very
highly specific DNA nuclease that would be appropriate
for most if not all applications. Today’s computation
design programs can help find target sites with minimal
similarity to off-targets in a reference genome, but em-
pirical testing in the appropriate cell type will likely be
required to ensure optimal specificity performance. With
more data sets of sgRNAs with SpCas9 and others in well
annotated genomes and epigenomes, improved compu-
tational approaches will likely reduce the need for
empirical testing to produce specific CRISPR/Cas9
nucleases and gene regulators.
Acknowledgements
The authors would like to acknowledge support from the W.M. Keck
Foundation and the National Institutes of Health (GM097073 and
HG006761).www.sciencedirect.com
How specific is CRISPR/Cas9 really? O’Geen, Yu and Segal 77References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA,
Charpentier E: A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity. Science 2012,
337:816-821.
2.

Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK,
Sander JD: High-frequency off-target mutagenesis induced by
CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013,
31:822-826.
First large study to demonstrate that some sgRNA promote promiscous
off-target clevage events, with some off-target sites used as much or
more often than the on-target site. However, other sgRNAs in this study
showed no off-target activity.
3.

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S,
Agarwala V, Li Y, Fine EJ, Wu X, Shalem O et al.: DNA targeting
specificity of RNA-guided Cas9 nucleases. Nat Biotechnol
2013, 31:827-832.
Pulbished in the same issue as Fu et al., this study found only intermediate
levels of off-target activity, presenting CRISPR/Cas as fairly specific.
4. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim JS: Analysis
of off-target effects of CRISPR/Cas-derived RNA-guided
endonucleases and nickases. Genome Res 2014, 24:132-141.
5. Cradick TJ, Fine EJ, Antico CJ, Bao G: CRISPR/Cas9 systems
targeting beta-globin and CCR5 genes have substantial off-
target activity. Nucl Acids Res 2013, 41:9584-9592.
6. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR: High-
throughput profiling of off-target DNA cleavage reveals RNA-
programmed Cas9 nuclease specificity. Nat Biotechnol 2013,
31:839-843.
7. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S,
Yang L, Church GM: Cas9 transcriptional activators for target
specificity screening and paired nickases for cooperative
genome engineering. Nat Biotechnol 2013, 31:833-838.
8. Koo T, Lee J, Kim JS: Measuring and reducing off-target
activities of programmable nucleases including CRISPR-
Cas9. Mol Cells 2015, 38:475-481.
9. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D,
Goodwin MJ, Aryee MJ, Joung JK: Dimeric CRISPR RNA-guided
FokI nucleases for highly specific genome editing. Nat
Biotechnol 2014, 32:569-576.
10. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S,
Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F:
Double nicking by RNA-guided CRISPR-Cas9 for enhanced
genome editing specificity. Cell 2013, 154:1380-1389.
11. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK: Improving
CRISPR-Cas nuclease specificity using truncated guide
RNAs. Nat Biotechnol 2014, 32:279-284.
12. Wyvekens N, Topkar VV, Khayter C, Joung JK, Tsai SQ: Dimeric
CRISPR RNA-guided FokI-dCas9 nucleases (RFNs) directed
by truncated gRNAs for highly specific genome editing.
Hum Gene Therapy 2015, 26:425-431.
13.

Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N,
Wile BM, Vertino PM, Stewart FJ, Bao G: CRISPR/Cas9 systems
have off-target activity with insertions or deletions between
target DNA and guide RNA sequences. Nucl Acids Res 2014,
42:7473-7485.
This study was the first to demonstrate that some sgRNAs could tolerate
DNA and RNA bulges, revealing a class of off-target sites that had been
unknown. Even now, most computational design programs do not con-
sider bulges.
14.

Xu H, Xiao T, Chen CH, Li W, Meyer CA, Wu Q, Wu D, Cong L,
Zhang F, Liu JS et al.: Sequence determinants of improved
CRISPR sgRNA design. Genome Res 2015, 25:1147-1157.
This is perhaps the most comprensive analysis of sequence features that
contribute to sgRNA efficiencies to date.www.sciencedirect.com 15. MacPherson CR, Scherf A: Flexible guide-RNA design for
CRISPR applications using protospacer workbench. Nat
Biotechnol 2015, 33:805-806.
16. Bae S, Park J, Kim JS: Cas-offinder: a fast and versatile algorithm
that searches for potential off-target sites of Cas9 RNA-guided
endonucleases. Bioinformatics 2014, 30(10):1473-1475.
17. Montague TG, Cruz JM, Gagnon JA, Church GM, Valen E:
CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome
editing. Nucl Acids Res 2014, 42(Web Server issue):W401-W407.
18. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-
Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA:
CRISPR-mediated modular RNA-guided regulation of
transcription in eukaryotes. Cell 2013, 154:442-451.
19. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM,
Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW et al.:
RNA-guided gene activation by CRISPR-Cas9-based
transcription factors. Nat Methods 2013, 10:973-976.
20. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK:
CRISPR RNA-guided activation of endogenous human genes.
Nat Methods 2013, 10:977-979.
21. Hilton IB, D’Ippolito AM, Vockley CM, Thakore PI, Crawford GE,
Reddy TE, Gersbach CA: Epigenome editing by a CRISPR-
Cas9-based acetyltransferase activates genes from
promoters and enhancers. Nat Biotechnol 2015, 33:510-517.
22. Kearns NA, Pham H, Tabak B, Genga RM, Silverstein NJ,
Garber M, Maehr R: Functional annotation of native enhancers
with a cas9-histone demethylase fusion. Nat Methods 2015,
12:401-403.
23. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP,
Lim WA: Repurposing CRISPR as an RNA-guided platform for
sequence-specific control of gene expression. Cell 2013,
152:1173-1183.
24. O’Geen H, Henry IM, Bhakta MS, Meckler JF, Segal DJ: A
genome-wide analysis of Cas9 binding specificity using ChIP-
seq and targeted sequence capture. Nucl Acids Res 2015,
43:3389-3404.
25. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, Cheng AW,
Trevino AE, Konermann S, Chen S et al.: Genome-wide binding of
the CRISPR endonuclease Cas9 in mammalian cells. Nat
Biotechnol 2014, 32:670-676.
26. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M: Genome-wide
analysis reveals characteristics of off-target sites bound by
the Cas9 endonuclease. Nat Biotechnol 2014, 32:677-683.
27. Cencic R, Miura H, Malina A, Robert F, Ethier S, Schmeing TM,
Dostie J, Pelletier J: Protospacer adjacent motif (PAM)-distal
sequences engage CRISPR Cas9 DNA target cleavage. PloS
One 2014, 9:e109213.
28. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA: DNA
interrogation by the CRISPR RNA-guided endonuclease Cas9.
Nature 2014, 507:62-67.
29. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI,
Dohmae N, Ishitani R, Zhang F, Nureki O: Crystal structure of
Cas9 in complex with guide RNA and target DNA. Cell 2014,
156:935-949.
30. Smith C, Gore A, Yan W, Abalde-Atristain L, Li Z, He C, Wang Y,
Brodsky RA, Zhang K, Cheng L, Ye Z: Whole-genome
sequencing analysis reveals high specificity of CRISPR/Cas9
and TALEN-based genome editing in human iPSCs. Cell Stem
Cell 2014, 15:12-13.
31. Veres A, Gosis BS, Ding Q, Collins R, Ragavendran A, Brand H,
Erdin S, Cowan CA, Talkowski ME, Musunuru K: Low incidence of
off-target mutations in individual CRISPR-Cas9 and TALEN
targeted human stem cell clones detected by whole-genome
sequencing. Cell Stem Cell 2014, 15:27-30.
32. Yang L, Grishin D, Wang G, Aach J, Zhang CZ, Chari R, Homsy J,
Cai X, Zhao Y, Fan JB, Seidman C: Targeted and genome-wide
sequencing reveal single nucleotide variations impacting
specificity of Cas9 in human stem cells. Nat Commun 2014,
5:5507.Current Opinion in Chemical Biology 2015, 29:72–78
78 Mechanistic biology33. Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim JI,
Kim JS: Digenome-seq: genome-wide profiling of CRISPR-
Cas9 off-target effects in human cells. Nat Methods 2015,
12:237-243.
34. Wu X, Kriz AJ, Sharp PA: Target specificity of the CRISPR-Cas9
system. Quantitative Biol 2014, 2:59-70.
35. Wang X, Wang Y, Wu X, Wang J, Wang Y, Qiu Z, Chang T,
Huang H, Lin RJ, Yee JK: Unbiased detection of off-target
cleavage by CRISPR-Cas9 and TALENs using integrase-
defective lentiviral vectors. Nat Biotechnol 2015, 33:175-178.
36. Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P,
Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G,
Holmes MC: An unbiased genome-wide analysis of zinc-finger
nuclease specificity. Nat Biotechnol 2011, 29:816-823.
37. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V,
Wyvekens N, Khayter C, Iafrate AJ, Le LP et al.: GUIDE-seq
enables genome-wide profiling of off-target cleavage by
CRISPR-Cas nucleases. Nat Biotechnol 2015, 33:187-197.
38. Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW: Genome-wide
detection of DNA double-stranded breaks induced by
engineered nucleases. Nat Biotechnol 2015, 33:179-186.Current Opinion in Chemical Biology 2015, 29:72–78 39. Pratto F, Brick K, Khil P, Smagulova F, Petukhova GV, Camerini-
Otero RD: DNA recombination. Recombination initiation
maps of individual human genomes. Science 2014,
346:1256442.
40. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM:
Orthogonal Cas9 proteins for RNA-guided gene regulation
and editing. Nat Methods 2013, 10:1116-1121.
41.

Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ,
Zetsche B, Shalem O, Wu X, Makarova KS et al.: In vivo genome
editing using Staphylococcus aureus Cas9. Nature 2015,
520:186-191.
This is the first off-target analysis of a Cas9 ortholog. It also describes one
of the third generation methods (BLESS) for the direct detection of double
strand breaks.
42. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M,
Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE: Rational
design of highly active sgRNAs for CRISPR-Cas9-mediated
gene inactivation. Nat Biotechnol 2014, 32:1262-1267.
43. Consortium EP, Bernstein BE, Birney E, Dunham I, Green ED,
Gunter C, Snyder M: An integrated encyclopedia of DNA
elements in the human genome. Nature 2012, 489:57-74.www.sciencedirect.com
